532 related articles for article (PubMed ID: 7553621)
1. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB
Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621
[TBL] [Abstract][Full Text] [Related]
2. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
3. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Herman JG; Jen J; Merlo A; Baylin SB
Cancer Res; 1996 Feb; 56(4):722-7. PubMed ID: 8631003
[TBL] [Abstract][Full Text] [Related]
5. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.
Reed AL; Califano J; Cairns P; Westra WH; Jones RM; Koch W; Ahrendt S; Eby Y; Sewell D; Nawroz H; Bartek J; Sidransky D
Cancer Res; 1996 Aug; 56(16):3630-3. PubMed ID: 8705996
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma.
Maesawa C; Tamura G; Nishizuka S; Ogasawara S; Ishida K; Terashima M; Sakata K; Sato N; Saito K; Satodate R
Cancer Res; 1996 Sep; 56(17):3875-8. PubMed ID: 8752149
[TBL] [Abstract][Full Text] [Related]
7. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP
Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506
[TBL] [Abstract][Full Text] [Related]
9. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
Costello JF; Berger MS; Huang HS; Cavenee WK
Cancer Res; 1996 May; 56(10):2405-10. PubMed ID: 8625319
[TBL] [Abstract][Full Text] [Related]
10. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
11. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia.
Batova A; Diccianni MB; Yu JC; Nobori T; Link MP; Pullen J; Yu AL
Cancer Res; 1997 Mar; 57(5):832-6. PubMed ID: 9041181
[TBL] [Abstract][Full Text] [Related]
12. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
[TBL] [Abstract][Full Text] [Related]
13. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
14. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Schutte M; Hruban RH; Geradts J; Maynard R; Hilgers W; Rabindran SK; Moskaluk CA; Hahn SA; Schwarte-Waldhoff I; Schmiegel W; Baylin SB; Kern SE; Herman JG
Cancer Res; 1997 Aug; 57(15):3126-30. PubMed ID: 9242437
[TBL] [Abstract][Full Text] [Related]
16. [Tribulations of the p16/MTS1/CDKN2 tumor gene suppressor: a continuing saga].
Larsen CJ
Bull Cancer; 1997 Apr; 84(4):427-30. PubMed ID: 9238169
[TBL] [Abstract][Full Text] [Related]
17. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain.
Zhang SJ; Endo S; Ichikawa T; Washiyama K; Kumanishi T
Cancer Res; 1998 Mar; 58(6):1231-7. PubMed ID: 9515810
[TBL] [Abstract][Full Text] [Related]
18. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
19. High frequency of p16INK4A gene alterations in hepatocellular carcinoma.
Liew CT; Li HM; Lo KW; Leow CK; Chan JY; Hin LY; Lau WY; Lai PB; Lim BK; Huang J; Leung WT; Wu S; Lee JC
Oncogene; 1999 Jan; 18(3):789-95. PubMed ID: 9989830
[TBL] [Abstract][Full Text] [Related]
20. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines.
Gonzalgo ML; Hayashida T; Bender CM; Pao MM; Tsai YC; Gonzales FA; Nguyen HD; Nguyen TT; Jones PA
Cancer Res; 1998 Mar; 58(6):1245-52. PubMed ID: 9515812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
